PREVALITE- cholestyramine powder, for suspension

United States - English - NLM (National Library of Medicine)

Buy It Now

Active ingredient:
cholestyramine (UNII: 4B33BGI082) (cholestyramine - UNII:4B33BGI082)
Available from:
Upsher-Smith Laboratories, LLC
INN (International Name):
cholestyramine
Composition:
cholestyramine 4 g in 5.5 g
Administration route:
ORAL
Prescription type:
PRESCRIPTION DRUG
Therapeutic indications:
1) Prevalite® (cholestyramine for oral suspension, USP) powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Prevalite® (cholestyramine for oral suspension, USP) powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug
Product summary:
Prevalite® (cholestyramine for oral suspension, USP) powder is available in cartons of forty-two and sixty single-dose packets and in cans containing 231 grams. 5.5 grams of Prevalite® (cholestyramine for oral suspension, USP) powder contain 4 grams of anhydrous cholestyramine resin. Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Authorization status:
Abbreviated New Drug Application
Authorization number:
0245-0036-23, 0245-0036-42, 0245-0036-60, 0245-0036-89

PREVALITE- cholestyramine powder, for suspension

Upsher-Smith Laboratories, LLC

----------

Prevalite

(Cholestyramine for Oral Suspension, USP)

Rx only

DESCRIPTION

Prevalite

(cholestyramine for oral suspension, USP) powder, the chloride salt of a basic anion

exchange resin, a cholesterol-lowering agent, is intended for oral administration. Cholestyramine resin

is quite hydrophilic, but insoluble in water. The cholestyramine resin in Prevalite

(cholestyramine for

oral suspension, USP) is not absorbed from the digestive tract. 5.5 grams of Prevalite

(cholestyramine

for oral suspension, USP) contain 4 grams of anhydrous cholestyramine resin. It is represented by the

following structural formula:

Prevalite

(cholestyramine for oral suspension, USP) powder contains the following inactive

ingredients: aspartame, FD&C Yellow No. 6, malic acid, polysorbate 80, propylene glycol alginate, and

orange flavor.

CLINICAL PHARMACOLOGY

Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are

secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and

returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in

normal serum.

Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble

complex which is excreted in the feces. This results in a partial removal of bile acids from the

enterohepatic circulation by preventing their absorption.

The increased fecal loss of bile acids due to cholestyramine resin administration leads to an increased

oxidation of cholesterol to bile acids, a decrease in beta lipoprotein or low density lipoprotein plasma

levels and a decrease in serum cholesterol levels. Although in man, cholestyramine resin produces an

increase in hepatic synthesis of cholesterol, plasma cholesterol levels fall.

In patients with partial biliary obstruction, the reduction of serum bile acid levels by cholestyramine

resin reduces excess bile acids deposited in the dermal tissue with resultant decrease in pruritus.

Clinical Studies

In a large, placebo-controlled, multi-clinic study, LRC-CPPT , hypercholesterolemic subjects treated

with cholestyramine resin had mean reduction in total and low-density lipoprotein cholesterol (LDL-C)

which exceeded those for diet and placebo treatment by 7.2% and 10.4%, respectively. Over the seven-

year study period the cholestyramine resin group experienced a 19% reduction (relative to the

incidence in the placebo group) in the combined rate of coronary heart disease death plus non-fatal

®

myocardial infarction (cumulative incidence of 7% cholestyramine resin and 8.6% placebo). The

subjects included in the study were men aged 35 to 59 with serum cholesterol levels above 265 mg/dL

and no previous history of heart disease. It is not clear to what extent these findings can be extrapolated

to females and other segments of the hypercholesterolemic population (see also PRECAUTIONS,

Carcinogenesis, Mutagenesis, Impairment of Fertility).

Two controlled clinical trials have examined the effects of cholestyramine monotherapy upon coronary

atherosclerotic lesions using coronary arteriography. In the NHLBI Type II Coronary Intervention

T rial

, 116 patients (80% male) with coronary artery disease (CAD) documented by arteriography were

randomized to cholestyramine resin or placebo for five years of treatment. Final study arteriography

revealed progression of coronary artery disease in 49% of placebo patients compared to 32% of the

cholestyramine resin group (p<0.05).

In the St. Thomas Atherosclerosis Regression Study (STARS) , 90 hypercholesterolemic men with

CAD were randomized to three blinded treatments: usual care, lipid-lowering diet and lipid-lowering

diet plus cholestyramine resin. After 36 months, follow-up coronary arteriography revealed

progression of disease in 46% of usual care patients, 15% of patients on lipid-lowering diet and 12%

of those receiving diet plus cholestyramine resin (p<0.02). The mean absolute width of coronary

segments decreased in the usual care group, increased slightly (0.003 mm) in the diet group and

increased by 0.103 mm in the diet plus cholestyramine group (p<0.05). Thus in these randomized

controlled clinical trials using coronary arteriography, cholestyramine resin monotherapy has been

demonstrated to slow progression

and promote regression of atherosclerotic lesions in the coronary

arteries of patients with coronary artery disease.

The effect of intensive lipid-lowering therapy on coronary atherosclerosis has been assessed by

arteriography in hyperlipidemic patients. In these randomized, controlled clinical trials, patients were

treated for two to four years by either conventional measures (diet, placebo, or in some cases low dose

resin), or intensive combination therapy using diet plus colestipol (an anion exchange resin with a

mechanism of action and an effect on serum lipids similar to that of cholestyramine for oral suspension)

plus either nicotinic acid or lovastatin. When compared to conventional measures, intensive lipid-

lowering combination therapy significantly reduced the frequency of progression and increased the

frequency of regression of coronary atherosclerotic lesions in patients with or at risk for coronary

artery disease.

INDICATIONS AND USAGE

1) Prevalite

(cholestyramine for oral suspension, USP) powder is indicated as adjunctive therapy to

diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia

(elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Prevalite

(cholestyramine for oral suspension, USP) powder may be useful to lower LDL cholesterol in patients

who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the

abnormality of most concern.

Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those

individuals at significantly increased risk for atherosclerotic vascular disease due to

hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of

hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an

important factor and caloric restriction for weight normalization should be addressed prior to drug

therapy in the overweight.

Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g.,

poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive

liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to

assess Total Cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL

(<4.5 mmol/L), LDL-C can be estimated using the following equation:

LDL-C = Total Cholesterol - [(TG/5) + HDL-C]

For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be

determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal

despite elevated Total-C. In such cases cholestyramine resin may not be indicated.

Serum cholesterol and triglyceride levels should be determined periodically based on NCEP

guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol

reduction should occur during the first month of cholestyramine resin therapy. The therapy should be

continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing

the dosage of cholestyramine resin or adding other lipid-lowering agents in combination with

cholestyramine resin should be considered.

Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to

initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used

to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried

out once a year. The NCEP treatment guidelines are summarized below.

LDL-Cholesterol mg/dL (mmol/L)

Definite Atherosclerotic

Dis eas e

Two or More Other

Risk Factors

Initiation Level

Goal

≥190 (≥4.9)

<160 (<4.1)

≥160 (≥4.1)

<130 (<3.4)

Yes or No

≥130 (≥3.4)

≤100 (≤2.6)

Cholestyramine resin monotherapy has been demonstrated to retard the rate of progression

increase the rate of regression of coronary atherosclerosis.

2) Prevalite

(cholestyramine for oral suspension, USP) powder is indicated for the relief of pruritus

associated with partial biliary obstruction. Cholestyramine resin has been shown to have a variable

effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an

elevated cholesterol as part of their disease.

CONTRAINDICATIONS

Prevalite

powder is contraindicated in patients with complete biliary obstruction where bile is not

secreted into the intestine and in those individuals who have shown hypersensitivity to any of its

components.

WARNING

PHENYLKETONURICS: PREVALITE CONTAINS 14.1 mg PHENYLALANINE PER 5.5

GRAM DOSE.

PRECAUTIONS

General

Chronic use of cholestyramine resin may be associated with increased bleeding tendency due to

*

Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease)

Other risk factors for coronary heart disease (CHD) include: age (males ≥4 5 years; females: ≥55 years or

premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette

smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk

factor if HDL-C is ≥60 mg/dL (≥1.6 mmol/L).

®

hypoprothrombinemia associated with Vitamin K deficiency. This will usually respond promptly to

parenteral Vitamin K and recurrences can be prevented by oral administration of Vitamin K . Reduction

of serum or red cell folate has been reported over long term administration of cholestyramine resin.

Supplementation with folic acid should be considered in these cases.

There is a possibility that prolonged use of cholestyramine resin, since it is a chloride form of anion

exchange resin, may produce hyperchloremic acidosis. This would especially be true in younger and

smaller patients where the relative dosage may be higher. Caution should also be exercised in patients

with renal insufficiency or volume depletion and in patients receiving concomitant spironolactone.

Cholestyramine resin may produce or worsen pre-existing constipation. The dosage should be

increased gradually in patients to minimize the risk of developing fecal impaction. In patients with pre-

existing constipation, the starting dose should be 1 packet or 1 scoop once daily for 5 to 7 days,

increasing to twice daily with monitoring of constipation and of serum lipoproteins, at least twice, 4 to

6 weeks apart. Increased fluid intake and fiber intake should be encouraged to alleviate constipation and

a stool softener may occasionally be indicated. If the initial dose is well tolerated, the dose may be

increased as needed by one dose/day (at monthly intervals) with periodic monitoring of serum

lipoproteins. If constipation worsens or the desired therapeutic response is not achieved at one to six

doses/day, combination therapy or alternate therapy should be considered. Particular effort should be

made to avoid constipation in patients with symptomatic coronary artery disease. Constipation associated

with cholestyramine resin may aggravate hemorrhoids.

Information for Patients

Inform your physician if you are pregnant or plan to become pregnant or are breast-feeding. Drink

plenty of fluids and mix each 5.5 gram dose of Prevalite

(cholestyramine for oral suspension, USP)

powder in at least 2 to 3 ounces of fluid before taking. Sipping or holding the resin suspension in the

mouth for prolonged periods may lead to changes in the surface of the teeth resulting in discoloration,

erosion of enamel or decay; good oral hygiene should be maintained.

Laboratory Tests

Serum cholesterol levels should be determined frequently during the first few months of therapy and

periodically thereafter. Serum triglyceride levels should be measured periodically to detect whether

significant changes have occurred.

The LRC-CPPT showed a dose-related increase in serum triglycerides of 10.7% to 17.1% in the

cholestyramine-treated group, compared with an increase of 7.9% to 11.7% in the placebo group. Based

on the mean values and adjusting for the placebo group, the cholestyramine-treated group showed an

increase of 5% over pre-entry levels the first year of the study and an increase of 4.3% the seventh

year.

Drug Interactions

Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as

phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline,

penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins and digitalis.

Interference with the absorption of oral phosphate supplements has been observed with another

positively-charged bile acid sequestrant. Cholestyramine resin may interfere with the pharmacokinetics

of drugs that undergo enterohepatic circulation. The discontinuance of cholestyramine resin could pose

a hazard to health if a potentially toxic drug such as digitalis has been titrated to a maintenance level

while the patient was taking cholestyramine resin.

Because cholestyramine binds bile acids, cholestyramine resin may interfere with normal fat digestion

and absorption and thus may prevent absorption of fat soluble vitamins such as A, D, E and K. When

cholestyramine resin is given for long periods of time, concomitant supplementation with water-

miscible (or parenteral) forms of fat-soluble vitamins should be considered.

SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT

IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR

4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS

POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In studies conducted in rats in which cholestyramine resin was used as a tool to investigate the role of

various intestinal factors, such as fat, bile salts and microbial flora, in the development of intestinal

tumors induced by potent carcinogens, the incidence of such tumors was observed to be greater in

cholestyramine resin-treated rats than in control rats.

The relevance of this laboratory observation from studies in rats to the clinical use of cholestyramine

resin is not known. In the LRC-CPPT study referred to above, the total incidence of fatal and nonfatal

neoplasms was similar in both treatment groups. When the many different categories of tumors are

examined, various alimentary system cancers were somewhat more prevalent in the cholestyramine

group. The small numbers and the multiple categories prevent conclusions from being drawn. However,

in view of the fact that cholestyramine resin is confined to the GI tract and not absorbed and in light of

the animal experiments referred to above, a six-year post-trial follow-up of the LRC-CPPT patient

population has been completed (a total of 13.4 years of in-trial plus post-trial follow-up) and revealed

no significant difference in the incidence of cause-specific mortality or cancer morbidity between

cholestyramine and placebo treated patients.

Pregnancy

There are no adequate and well controlled studies in pregnant women. The use of cholestyramine in

pregnancy or lactation or by women of childbearing age requires that the potential benefits of drug

therapy be weighted against the possible hazards to the mother and child. Cholestyramine is not

absorbed systemically, however, it is known to interfere with absorption of fat-soluble vitamins;

accordingly, regular prenatal supplementation may not be adequate (see PRECAUTIONS, Drug

Interactions ).

Nursing Mothers

Caution should be exercised when cholestyramine resin is administered to a nursing mother. The

possible lack of proper vitamin absorption described in the "Pregnancy" section may have an effect on

nursing infants.

Pediatric Use

Although an optimal dosage schedule has not been established, standard texts

list a usual pediatric

dose of 240 mg/kg/day of anhydrous cholestyramine resin in two to three divided doses, normally not to

exceed 8 g/day with dose titration based on response and tolerance.

In calculating pediatric dosages, 80 mg of anhydrous cholestyramine resin are contained in 110 mg of

Prevalite

The effects of long-term drug administration, as well as its effect in maintaining lowered cholesterol

levels in pediatric patients, are unknown. Also see ADVERSE REACTIONS.

ADVERSE REACTIONS

The most common adverse reaction is constipation. When used as a cholesterol-lowering agent,

predisposing factors for most complaints of constipation are high dose and increased age (more than 60

years old). Most instances of constipation are mild, transient and controlled with conventional therapy.

Some patients require a temporary decrease in dosage or discontinuation of therapy.

Less Frequent Adverse Reactions: Abdominal discomfort and/or pain, flatulence, nausea, vomiting,

(6,7)

diarrhea, eructation, anorexia, steatorrhea, bleeding tendencies due to hypoprothrombinemia (Vitamin K

deficiency) as well as Vitamin A (one case of night blindness reported) and D deficiencies,

hyperchloremic acidosis in children, osteoporosis, rash and irritation of the skin, tongue and perianal

area. Rare reports of intestinal obstruction, including two deaths, have been reported in pediatric

patients.

Occasional calcified material has been observed in the biliary tree, including calcification of the

gallbladder, in patients to whom cholestyramine resin has been given. However, this may be a

manifestation of the liver disease and not drug related.

One patient experienced biliary colic on each of three occasions on which he took a cholestyramine for

oral suspension product. One patient diagnosed as acute abdominal symptom complex was found to have

a "pasty mass" in the transverse colon on x-ray.

Other events (not necessarily drug related) reported in patients taking cholestyramine resin include:

OVERDOSAGE

Overdosage of cholestyramine resin has been reported in a patient taking 150% of the maximum

recommended daily dosage for a period of several weeks. No ill effects were reported. Should an

overdosage occur, the chief potential harm would be obstruction of the gastrointestinal tract. The

location of such potential obstruction, the degree of obstruction, and the presence or absence of normal

gut motility would determine treatment.

DOSAGE AND ADMINISTRATION

The recommended starting adult dose for Prevalite

(cholestyramine for oral suspension, USP) powder

is one packet or one level scoopful (5.5 grams of Prevalite

[cholestyramine for oral suspension, USP]

powder contain 4 grams of anhydrous cholestyramine resin) once or twice a day. The recommended

maintenance dose for Prevalite

(cholestyramine for oral suspension, USP) powder is 2 to 4 packets or

scoopfuls daily (8 to 16 grams anhydrous cholestyramine resin) divided into two doses. It is

recommended that increases in dose be gradual with periodic assessment of lipid/lipoprotein levels at

intervals of not less than 4 weeks. The maximum recommended daily dose is six packets or scoopfuls of

Prevalite

(cholestyramine for oral suspension, USP) powder (24 grams of anhydrous cholestyramine

resin). The suggested time of administration is at mealtime but may be modified to avoid interference

with absorption of other medications. Although the recommended dosing schedule is twice daily,

Prevalite

(cholestyramine for oral suspension, USP) powder may be administered in 1 to 6 doses per

day.

Prevalite

(cholestyramine for oral suspension, USP) powder should not be taken in its dry form.

Always mix the dry powder with water or other fluids before ingesting. See Preparation

Gastrointestinal: GI-rectal bleeding, black stools, hemorrhoidal bleeding, bleeding from known

duodenal ulcer, dysphagia, hiccups, ulcer attack, sour taste, pancreatitis, rectal pain, diverticulitis.

Laboratory Test Changes: Liver function abnormalities.

Hematologic: Prolonged prothrombin time, ecchymosis, anemia.

Hypersensitivity: Urticaria, asthma, wheezing, shortness of breath.

Musculoskeletal: Backache, muscle and joint pains, arthritis.

Neurologic: Headache, anxiety, vertigo, dizziness, fatigue, tinnitus, syncope, drowsiness, femoral

nerve pain, paresthesia.

Eye: Uveitis.

Renal: Hematuria, dysuria, burnt odor to urine, diuresis.

Miscellaneous: Weight loss, weight gain, increased libido, swollen glands, edema, dental

bleeding, dental caries, erosion of tooth enamel, tooth discoloration.

®

Ins tructions .

Concomitant Therapy

Preliminary evidence suggests that the lipid-lowering effects of cholestyramine on total and LDL-

cholesterol are enhanced when combined with a HMG-CoA reductase inhibitor, e.g., pravastatin,

lovastatin, simvastatin and fluvastatin. Additive effects on LDL-cholesterol are also seen with combined

nicotinic acid/cholestyramine therapy. See PRECAUTIONS, Drug Interactions for recommendations

on administering concomitant therapy.

Preparation

The color of Prevalite

(cholestyramine for oral suspension, USP) powder may vary somewhat from

batch to batch but this variation does not affect the performance of the product. Place the contents of

one single-dose packet or one level scoopful of Prevalite

(cholestyramine for oral suspension, USP)

powder in a glass or cup. Add at least 2 to 3 ounces of water or the beverage of your choice. Stir to a

uniform consistency.

Prevalite

(cholestyramine for oral suspension, USP) powder may also be mixed with highly fluid

soups or pulpy fruits with a high moisture content such as applesauce or crushed pineapple.

HOW SUPPLIED

Prevalite

(cholestyramine for oral suspension, USP) powder is available in cartons of forty-two and

sixty single-dose packets and in cans containing 231 grams. 5.5 grams of Prevalite

(cholestyramine for

oral suspension, USP) powder contain 4 grams of anhydrous cholestyramine resin.

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP

Controlled Room Temperature].

REFERENCES

1. The Lipid Research Clinics Coronary Primary Prevention Trial Results: (I) Reduction in Incidence

of Coronary Heart Disease; (II) The Relationship of Reduction in Incidence of Coronary Heart

Disease to Cholesterol Lowering. JAMA. 1984; 251: 351-374.

2. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of

coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation

1984; 69: 313-24.

3. Watts GF, Lewis B, Brunt JNH, Lewis ES, et al. Effects on coronary artery disease of lipid-

lowering diet or diet plus cholestyramine, in the St. Thomas Atherosclerosis Regression Study

(STARS). Lancet 1992; 339: 563-69.

4. National Cholesterol Education Program. Second Report of the Expert Panel on Detection,

Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

Circulation 1994 Mar; 89(3): 1333-445.

5. The Lipid Research Clinics Investigators. The Lipid Research Clinics Coronary Primary

Prevention Trial Results of 6 Years of Post-Trial Follow-up. Arch Intern Med 1992; 152: 1399-

1410.

6. Behrman RE et al (eds): Nelson, Textbook of Pediatrics, ed 15. Philadelphia, PA, WB Saunders

Company, 1996.

7. Takemoto CK et al (eds): Pediatric Dosage Handbook, ed 3. Cleveland/Akron, OH, Lexi-Comp, Inc.,

1996/1997.

NDC 0245-0036-42 Cartons of 42, 5.5 g packets

NDC 0245-0036-60 Cartons of 60, 5.5 g packets

NDC 0245-0036-23 Cans, 231 g (42 doses)

To report SUSPECTED ADVERSE REACTIONS, contact Upsher-Smith Laboratories, LLC at

1-855-899-9180 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Prevalite is a registered trademark of Upsher-Smith Laboratories, LLC.

Manufactured by

UPSHER-SMITH LABORATORIES, LLC

Maple Grove, MN 55369

Revised: 6/2020

PRINCIPAL DISPLAY PANEL - 231 g Can Label

NDC 0245-0036-23

Prevalite

Powder

(Cholestyramine for Oral Suspension, USP)

Orange Flavor

4 grams cholestyramine

resin USP, per scoopful

Contains 231 g (168 g anhydrous cholestyramine resin)

42 measured doses

Rx only

Scoop enclosed

UPSHER-SMITH

®

PREVALITE

cholestyramine powder, for suspension

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:0 245-0 0 36

Route of Administration

ORAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

cho lestyra mine (UNII: 4B33BGI0 8 2) (cho lestyramine - UNII:4B33BGI0 8 2)

c ho le styra mine

4 g in 5.5 g

Inactive Ingredients

Ingredient Name

Stre ng th

a spa rta me (UNII: Z0 H242BBR1)

FD&C Yello w No . 6 (UNII: H77VEI9 3A8 )

ma lic a cid (UNII: 8 17L1N4CKP)

po lyso rba te 8 0 (UNII: 6 OZP39 ZG8 H)

pro pylene g lyco l a lg ina te (UNII: 26 CD3J2R0 C)

Upsher-Smith Laboratories, LLC

Product Characteristics

Color

S core

S hap e

S iz e

Flavor

ORANGE

Imprint Code

Contains

Packag ing

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:0 245-0 0 36 -42

42 in 1 CARTON

0 2/0 1/19 9 6

1

NDC:0 245-0 0 36 -8 9

5.5 g in 1 PACKET; Type 0 : No t a Co mbinatio n Pro duct

2

NDC:0 245-0 0 36 -6 0

6 0 in 1 CARTON

0 2/0 1/19 9 6

2

NDC:0 245-0 0 36 -8 9

5.5 g in 1 PACKET; Type 0 : No t a Co mbinatio n Pro duct

3

NDC:0 245-0 0 36 -23

231 g in 1 CAN; Type 0 : No t a Co mbinatio n Pro duct

0 2/0 1/19 9 6

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 7326 3

0 2/0 1/19 9 6

Labeler -

Upsher-Smith Laboratories, LLC (079111820)

Establishment

Name

Ad d re s s

ID/FEI

Busine ss Ope rations

Upsher-Smith Labo rato ries, LLC

0 79 1118 20

MANUFACTURE(0 245-0 0 36 ) , LABEL(0 245-0 0 36 ) , PACK(0 245-0 0 36 )

Establishment

Name

Ad d re s s

ID/FEI

Busine ss Ope rations

Upsher-Smith Labo rato ries, LLC

0 472510 0 4

ANALYSIS(0 245-0 0 36 )

Revised: 6/2020

Similar products

Search alerts related to this product

Share this information